secwatch.observer — SEC 8-K summary
======================================

Issuer:     Apogee Therapeutics, Inc. (APGE)
CIK:        0001974640
Form:       8-K
Filed at:   2024-08-19T23:59:59+00:00
Accession:  0001104659-24-090690
Event type: other_material
Sentiment:  positive
Materiality: 0.60
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Apogee doses first healthy volunteers in Phase 1 trial of OX40L antibody APG990 for atopic dermatitis
--------------------------------------------------------------------------------

- Initiated dosing in Phase 1 trial of APG990, a half-life extended OX40L antibody, enrolling ~40 healthy volunteers in 5 cohorts.
- Interim safety and pharmacokinetic data from the Phase 1 trial expected in 2025.
- Plans to start combination trial of APG777 (IL-13) and APG990 in 2025 for broader efficacy in atopic dermatitis.
- CEO Michael Henderson: three programs advanced into clinical trials in 12 months since company's inception.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1974640/000110465924090690/0001104659-24-090690-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1974640/000110465924090690/tm2421971d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-24-090690

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer